Login / Signup

TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy.

Humaira NoorNancy E BriggsKerrie L McDonaldJeff HolstOrazio Vittorio
Published in: Cancers (2021)
Based on these findings, we propose that certain TP53 mutant astrocytomas are chemosensitive through the involvement of YAP1, and we outline a potential mechanism. Thus, TP53 mutations may be key drivers of astrocytoma therapeutic efficacy and influence survival outcomes.
Keyphrases
  • prognostic factors
  • radiation therapy
  • risk assessment
  • human health
  • chemotherapy induced